切换至 "中华医学电子期刊资源库"
高级检索
中华消化病与影像杂志(电子版)

中华消化病与影像杂志(电子版) ›› 2018, Vol. 08 ›› Issue (01) : 24 -28. doi: 10.3877/cma.j.issn.2095-2015.2018.01.006

所属专题： 文献；

循证医学

替诺福韦酯与恩替卡韦在治疗慢性乙型肝炎的安全性与有效性的荟萃分析
尹丹萍1, 陈春明2,†()   
  1. 1. 250031　济南军区总医院疾病预防控制科
    2. 250031　济南军区总医院医务部
  • 收稿日期:2017-12-06 出版日期:2018-02-01
  • 通信作者: 陈春明
  • 基金资助:
    2015年度济南军区总医院院长基金(2015QN02)

Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis

Danping Yin1, Chunming Chen2,†()   

  1. 1. Department of Disease Prevention and Contrl, General Hospital of Jinan Military Command, Jinan 250031, China
    2. Department of Medical Administration, General Hospital of Jinan Military Command, Jinan 250031, China
  • Received:2017-12-06 Published:2018-02-01
  • Corresponding author: Chunming Chen
  • About author:
    Corresponding author: Chen Chunming, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

尹丹萍, 陈春明. 替诺福韦酯与恩替卡韦在治疗慢性乙型肝炎的安全性与有效性的荟萃分析[J]. 中华消化病与影像杂志(电子版), 2018, 08(01): 24-28.

Danping Yin, Chunming Chen. Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(01): 24-28.

目的

评估与比较恩替卡韦与替诺福韦酯在治疗慢性慢性乙型肝炎有效性及安全性。

方法

检索Pubmed/Medicine、Embase、Cochrane library数据库，恩替卡韦与替诺福韦酯治疗慢性乙型肝炎的研究，检索时间从数据库建立至2017年11月，由2名作者对检索数据进行提取与总结，运用Stata 12.0对数据进行统计学分析。

结果

共纳入此次荟萃分析共13篇，替诺福韦酯与恩替卡韦治疗HBV-DNA有效性方面，按照口服抗病毒药物时间，可分为2个亚组，24、48周其相对危险度与可信区间分别为：RR＝1.00，95% CI(0.90～1.11)，I2＝30%，P＝0.152；RR＝1.08，95% CI(1.00～1.16)，I2＝53%，P＝0.016。

结论

随访时间为24和48周时，在治疗慢性乙型肝炎HBV-DNA转阴率方面二者疗效相当。

关键词: 替诺福韦酯, 恩替卡韦, 慢性乙型肝炎, Meta分析
Objective

To evaluate and compare the efficacy and safety of entecavir and tenofovir in treatment of chronic hepatitis B.

Methods

The researches on entecavir and tenofovir in treatment of chronic hepatitis B were searched in PubMed/Medicine, EMBase, Cochrane Library databases until November 2017.Two authors independently extracted and summarized the data.Stata 12.0 software was used to analyze the data.

Results

A total of 13 studies were included in this Meta-analysis.In the aspect of therapeutic effectiveness of tenofovir and entecavir for HBV-DNA, the research objects were divided into two subgroups according to the use time of oral antiviral drug, and the relative risk(RR)and confidence interval(CI)of 24 weeks and 48 weeks subgroup were as follows: RR=1.00, 95% CI(0.90-1.11), I2=30%, P=0.152; RR=1.08, 95% CI(1.00-1.16), I2=53%, P=0.016.

Conclusion

Tenofovir has a similar efficacy in HBV-DNA negative conversion ratio compared with entecavir in follow-up time 24 and 48 weeks.

Key words: Tenofovir, Entecavir, Chronic hepatitis B, Meta-analysis
图1 随访时间为24周二者在治疗HBV-DNA有效性方面对比
图2 随访时间为48周二者在治疗HBV-DNA有效性方面对比
图3 随访时间为48周二者在治疗HBV-DNA有效性方面敏感性分析
图4 随访时间为48周二者在治疗HBV-DNA有效性方面Begg′s检验
1
World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic Hepatitis B infection[R]. Geneva: WHO, 2015.
2
European Association for the Study of the Liver.EASL 2017 Clinical practice guildelines on the management of Hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
3
Park JW, Kwak KM, Kim SE, et al.Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients[J]. BMC Gastroenterol, 2017, 17: 39.
4
Wu IT, Hu TH, Hung CH, et al.Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naïve chronic hepatitis B patients with high viremia: a retrospective cohort study[J]. Clin Microbiol Infect, 2017, 23(7): 464-469.
5
Pereira CV, Tovo CV, Grossmann TK, et al.Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil[J]. Mem Inst Oswaldo Cruz, 2016, 111(4): 252-257.
6
Centeno BL, Borrell RC, Encinas MP, et al.Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B[J]. Farm Hosp, 2016, 40(4): 279-286.
7
Shi H, Huang M, Lin G, et al.Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA[J]. Biomed Res Int, 2016, 2016: 6725073.
8
Yu HM, Kwon SY, Kim J, et al.Virologic response and safety of tenofovir versus entecavir in treatment-naive chronic Hepatitis B patients[J]. Saudi J Gastroenterol, 2015, 21(3): 146-151.
9
Gao L, Trinh HN, Li J, et al.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA Nguyen[J]. Aliment Pharmacol Ther, 2014, 39(6): 629-637.
10
Ha NB, Trinh HN, Rosenblatt L, et al.Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice[J]. J Clin Gastroenterol, 2016, 50(2): 169-174.
11
Güzelbulut F, Ovünç AO, Oetinkaya ZA, et al.Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B[J]. Hepatogastroenterology, 2012, 59(114): 477-480.
12
Ozaras R, Mete B, Ceylan B, et al.First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment[J]. Eur J Gastroenterol Hepatol, 2014, 26(7): 774-780.
13
Kwon YJ, Lee HS, Park MJ, et al.Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B[J]. Niger J Clin Pract, 2015, 18(6): 796-801.
14
Jayakumar R1, Joshi YK, Singh S. Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir[J]. J Lab Physicians, 2012, 4(1): 10-16.
15
Dogan Z, Filik L, Ergül B, et al.Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis[J]. Saudi J Gastroenterol, 2015, 21(6): 396-399.
16
Yegin EG, Ozdogan OC.Partial virological response to three different nucleotide analogues in na？ve patients with chronic hepatitis B [J]. Hepatobiliary Pancreat Dis Int, 2014, 13(6): 602-611.
17
安纪红．恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎患者48周临床分析[J]．中华传染病杂志，2012，30(11): 699-701.
18
Liaw YF, Sheen IS, Lee CM, et al.Tenofovir disoproxil fumarate(TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease [J]. Hepatology, 2011, 53(1): 62-72.
19
Sriprayoon T, Lueangarum S, Suwanwela C, et al.Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial [J]. Gastroenterology, 2012, 142: S695.
20
Tien C, Xu JJ, Chan LS, et al.Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling [J]. Dig Dis Sci, 2015, 60(2): 566-572.
21
Miquel M, Núñez O, Trapero-Marugán M, et al.Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice [J]. Ann Hepatol, 2013, 12(2): 205-212.
[1] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[2] 罗旺林, 杨传军, 许国星, 俞建国, 孙伟东, 颜文娟, 冯志. 开放性楔形胫骨高位截骨术不同植入材料的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 818-826.
[3] 马鹏程, 刘伟, 张思平. 股骨髋臼撞击综合征关节镜手术中闭合关节囊的疗效影响[J]. 中华关节外科杂志(电子版), 2023, 17(05): 653-662.
[4] 陈宏兴, 张立军, 张勇, 李虎, 周驰, 凡一诺. 膝骨关节炎关节镜清理术后中药外用疗效的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(05): 663-672.
[5] 邢阳, 何爱珊, 康焱, 杨子波, 孟繁钢, 邬培慧. 前交叉韧带单束联合前外侧结构重建的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(04): 508-519.
[6] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[7] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[8] 武慧铭, 郭仁凯, 李辉宇. 机器人辅助下经自然腔道取标本手术治疗结直肠癌安全性和有效性的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(05): 395-400.
[9] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[10] 张成仁, 杨熊飞, 杜斌斌, 柳利利, 李晶晶, 朱成章, 吴德望, 吕耀春. 转移灶不可切除的无症状结直肠癌是否行原发灶肿瘤切除术的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 305-310.
[11] 丁相元, 任效瑛, 闫慧明. Desarda与Lichtenstein术对腹股沟疝疗效的Meta分析[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(03): 255-263.
[12] 刘佳铭, 孙晓容, 文健, 何晓丽, 任茂玲. 有氧运动对成人哮喘肺功能、生活质量以及哮喘控制影响的Meta分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 592-595.
[13] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[14] 杨海龙, 邓满军, 樊羿辰, 徐梦钰, 陈芳德, 吴威浩, 张生元. 腹腔镜胆总管探查术一期缝合术后胆漏危险因素Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 545-550.
[15] 徐红莉, 杨钰琳, 薛清, 张茜, 马丽虹, 邱振刚. 体外冲击波治疗非特异性腰痛疗效的系统评价和Meta分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(05): 307-314.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号